➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Baxter
AstraZeneca
Johnson and Johnson
Moodys

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 7,459,601

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,459,601
Title:Human .alpha. synuclein expressing transgenic mice
Abstract: In methods for screening treatments for, and treatment of, neurodegenerative diseases, aggregation in neurons of NACP/.alpha.-synuclein is measured and expression of a non-amyloidogenic protein is stimulated in order to reduce the level aggregration. For purposes of screening agents for treatment of neurodegenerative disease, oxidative stress in the neuronal cells is stimulated by introducing a mixture of metal-ions and hydrogen peroxide. Examples of appropriate metals include iron, aluminum, and copper. After introduction of the agent under evaluation for stimulation of expression of non-amyloidogenic protein, the effectiveness is measured by testing for a decrease in the level of aggregation of NACP/.alpha.-synuclein. In an exemplary embodiment, the non-amyloidogenic protein is .beta.-synuclein. The aggregation of NACP/.alpha.-synuclein is dependent upon the concentration of metal ions in the neuronal cells. In addition, the presence of chelating agents appears to modulate the build-up of NACP/.alpha.-synuclein aggregates which are responsible for synaptic and neuronal dysfunction.
Inventor(s): Masliah; Eliezer (San Diego, CA), Hashimoto; Makoto (La Jolla, CA), Rockenstein; Edward (Chula Vista, CA), Mucke; Lennart (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:10/853,774
Patent Claims:see list of patent claims

Details for Patent 7,459,601

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2018-10-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Merck
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.